






Supplementary Figure 1 Participant flow diagram. Flow of patients through the study, describing the initial patients enrolled, subsequent exclusions, and the final patient cohorts analyzed for one-year clinical efficacy and endoscopic remission. N indicates the number of patients.

A**B**

Supplementary Figure 2 Kaplan-Meier curves of upadacitinib corticosteroid- and intensification-free persistence. A: Upadacitinib corticosteroid-free persistence rate between patients with ulcerative colitis and Crohn's disease; B: Upadacitinib intensification-free persistence rate between patients with ulcerative colitis and Crohn's disease. The blue line represents patients with ulcerative colitis, and the green line represents patients with Crohn's disease. Crohn's disease and Ulcerative colitis did not differ in these secondary outcomes.

Supplementary Table 1 Demographics and disease-related characteristics of 40 patients with Crohn's disease and ulcerative colitis who underwent endoscopy under upadacitinib and 45 who did not

	Underwent endoscopy <i>n</i> = 40	Did not undergo endoscopy <i>n</i> = 45	<i>P</i>
Age in years, mean (SD)	40.4 (13.0)	39.9 (13.2)	0.845 ^a
Male sex, <i>n</i> (%)	19 (47.5)	25 (55.6)	0.458 ^b
Disease duration in years, median (IQR)	6.5 (2.3–13.8)	6 (2–12)	0.459 ^c
Crohn's disease, <i>n</i> (%)	17 (42.5)	26 (57.8)	0.160 ^b
Montreal classification, <i>n</i> (%)			
UC – E (1/2/3), <i>n</i> (%)	1 (4.3) / 10 (43.5) / 12 (52.2)	3 (15.8) / 7 (36.8) / 9 (47.4)	0.451 ^b
CD – A (1/2/3), <i>n</i> (%)	1 (5.9) / 14 (82.4) / 2 (11.8)	2 (7.7) / 18 (69.2) / 6 (23.1)	0.609 ^b
CD – L (1/2/3), <i>n</i> (%)	2 (11.8) / 4 (23.5) / 11 (64.7)	14 (53.8) / 2 (7.7) / 10 (38.5)	0.017 ^b

CD - B (1/2/3), <i>n</i> (%)	11 (64.7) / 6 (35.3) / 0 (0)	12 (46.2) / 12 (46.2) / 2 (7.7)	0.323 ^b
CD - L4, <i>n</i> (%)	2 (11.8)	2 (7.7)	0.715 ^b
CD - p, <i>n</i> (%)	7 (41.2)	5 (19.2)	0.117 ^b
History of IBD-related surgery in CD, <i>n</i> (%)	6 (35.3)	11 (40.7)	0.718 ^b
Extraintestinal manifestations, <i>n</i> (%)	21 (52.5)	21 (47.7)	0.591 ^b
Articular manifestations, <i>n</i> (%)	17 (42.5)	16 (36.4)	0.512 ^b
Dermatologic manifestations, <i>n</i> (%)	4 (10)	11 (25)	0.065 ^b
Ocular manifestations, <i>n</i> (%)	1 (2.5)	0 (0)	0.471 ^d
Other, <i>n</i> (%)	4 (10)	4 (9.1)	0.861 ^b
Number of prior AT-0 / 1 / 2 / 3 / 4, <i>n</i> (%)	0 (0) / 10 (25) / 14 (35) / 14 (35) / 2 (5)	1 (2.3) / 13 (29.5) / 20 (45.5) / 11 (25) / 0 (0)	0.339 ^b

Median number of prior advanced therapies, (IQR)	2 (1.3-3)	2 (1-2.5)	0.151 ^c
prior anti-TNF exposure, <i>n</i> (%)	36 (90)	41 (93.2)	0.598 ^b
prior ustekinumab exposure, <i>n</i> (%)	22 (55)	21 (47.7)	0.505 ^b
prior vedolizumab exposure, <i>n</i> (%)	12 (30)	8 (18.2)	0.185 ^b
prior tofacitinib exposure, <i>n</i> (%)	5 (12.5)	3 (6.8)	0.376 ^b
Concomitant corticosteroids initiation, <i>n</i> (%)	at 15 (37.5))	19 (43.2)	0.657 ^b

^a *t* test; ^b χ^2 test; ^c *Mann-Whitney U* test; ^d *Fisher's* exact test

Only patients with ulcerative colitis and Crohn's disease were included in this analysis; patients with indefinite colitis or pouchitis were excluded.

CD: Crohn's disease; IBD: Inflammatory bowel disease; IQR: Interquartile range; P: P value; SD: Standard deviation; TNF: Tumor necrosis factor; UC: Ulcerative colitis.

Supplementary Table 2 Characteristics of adverse events recorded in our cohort, including severity and seriousness. Severity was graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 6.0[1]. Seriousness was defined in accordance with the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) E2A guidelines [2].

Adverse Category	Event	Total Events	Severity (CTCAE)	Grade	Seriousness (Serious, Non-serious)
Infections (excluding Herpes Zoster)		25	1 (n=1), 2 (n=22), 3 (n=2)		Serious (n=2), non-serious (n=23)
Herpes Zoster		2	2 (n=2)		Non-serious (n=2)
Acne		19	1 (n=17), 2 (n=2)		Non-serious (n=19)
Lipid profile alterations		15	1 (n=12), 2 (n=3)		Non-serious (n=15)
CPK elevation		12	1 (n=11), 3 (n=1)		Serious (n=1), non-serious (n=11)
Transaminase elevation		6	1 (n=5), 2 (n=1)		Non-serious (n=6)
Other					
Hair loss		2	1 (n=2)		Non-serious (n=2)
Hidradenitis suppurativa		1	3		Non-serious

flare			
Migraine	1	1	Non-serious
Creatinine elevation	1	1	Non-serious
Erythema multiforme	1	3	Non-serious
Skin rash	1	1	Non-serious
Leukopenia	1	1	Non-serious

CTCAE: Common Terminology Criteria for Adverse Events; CPK: Creatine phosphokinase; *n*: number of events.

References for Supplementary Table 2.

1. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 6.0. Published July 2025. Accessed September 3, 2026.
2. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline: Clinical Safety Data Management: Definitions and Standards for Expedited Reporting E2A. Published October 27, 1994.